You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed Cell Death Receptor Ligand 1 (PD-L1)

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

Completed
  • Neoplasm
  • Chuo-Ku, Japan
  • +1 more
Nov 3, 2022

Small Cell Lung Carcinoma Trial in Worldwide (coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830)

Active, not recruiting
  • Small Cell Lung Carcinoma
  • coformulation pembrolizumab/quavonlimab
  • +3 more
  • Gilbert, Arizona
  • +46 more
Jan 2, 2023

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Radiomics for prEdiction of lunG cAncer biologY

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • PET/CT
  • Poitiers, France
    CHU Poitiers
Apr 5, 2023

Immunotherapy in Upper Tract Urothelial Carcinoma

Not yet recruiting
  • Urothelial Carcinoma
  • Evaluation of anti-PD-(L)1 immunotherapy efficacy
  • (no location specified)
Oct 27, 2023

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

Recruiting
  • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
  • Montpellier, France
  • +7 more
Dec 19, 2022

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Germ Cell Tumor Trial in Milano (Durvalumab, Tremelimumab)

Terminated
  • Germ Cell Tumor
  • Milano, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
May 12, 2021

Esophageal Squamous Cell Carcinoma (ESCC) Trial in Japan, Taiwan (Pembrolizumab, Coformulation favezelimab/pembrolizumab,

Recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Pembrolizumab
  • +5 more
  • Milan, Lombardia, Italy
  • +13 more
Jan 3, 2023

Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

Not yet recruiting
  • Lung Neoplasm
  • +2 more
  • Tumor samples
  • Bordeaux, France
    CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
Aug 28, 2023

Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &

Terminated
Has Results
  • Metastatic Renal Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • New York, New York
    Weill Cornell Medicine - New York Presbyterian Hospital
Aug 26, 2021

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, Pembrolizumab)

Not yet recruiting
  • Advanced Non-small-cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 12, 2022

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Small Cell Lung Carcinoma (SCLC) Trial (BI 764532, Carboplatin, Etoposide)

Not yet recruiting
  • Small Cell Lung Carcinoma (SCLC)
  • BI 764532
  • +5 more
  • (no location specified)
Oct 17, 2023

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

Completed
Has Results
  • Neoplasms
  • Whittier, Alaska
  • +15 more
Aug 29, 2022

NSCLC Trial in Worldwide (Sacituzumab Govitecan-hziy (SG), Docetaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • Anchorage, Alaska
  • +104 more
Jul 20, 2022

Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Pembrolizumab/Vibostolimab coformuation, Docetaxel, Placebo)

Active, not recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Pembrolizumab/Vibostolimab coformuation
  • +2 more
  • Los Angeles, California
  • +94 more
Jan 4, 2023

Extensive Stage Small Cell Lung Cancer Trial (Tarlatamab, Carboplatin, Etoposide)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Los Angeles, California
  • +37 more
Feb 1, 2023

Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)

Recruiting
  • Donafenib
  • Donafenib, PD-1
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University,
Mar 4, 2022

Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)

Recruiting
  • Oncology
  • +2 more
  • UV1
  • +2 more
  • Drammen, Viken, Norway
    Vestre Viken Health Trust
Aug 15, 2022

Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

Not yet recruiting
  • Extensive-Stage Small Cell Lung Cancer
  • Beijing, China
    Chinese PLA General Hospital
Aug 18, 2022

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Melanoma Trial (biological, drug, radiation)

Withdrawn
  • Melanoma
  • Avelumab
  • +17 more
  • (no location specified)
Mar 17, 2021